Leucid Bio Provides Update on Phase I/IIa AERIAL Trial Evaluating Lateral CAR-T LEU011 for the Treatment of Solid Tumours
- Proof-of-concept established for LEU011 in the treatment of relapsed/refractory solid tumours
- LEU011 has been well tolerated, with disease control observed in multiple patients at lowest dose evaluated to date
- Enrolment continues in dose-escalation segment of the AERIAL trial with additional data for LEU011 anticipated during the first half of 2026
- Poster presentation of AERIAL trial presented at SITC 2025 Annual Meeting
London, UK – 10 November 2025 – Leucid Bio (“Leucid” or the “Company”), a privately-held biotechnology company developing innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies using its proprietary lateral CAR platform, today provided an update on the Phase I/IIa AERIAL trial evaluating the safety and clinical activity of LEU011 in patients with relapsed/refractory solid tumours.
